There have been no reported differences between RVX-208 treated patients and placebo treated patients with regard to the rate of investigator reported adverse events. The only exception is the transient elevation in the liver transaminases in a subset of patients that resolves itself within 2-3 weeks if I recall. See Dr. Sweeney's slides 57 and 58 from the R&D day earlier this month. He covers both the lack of serious adverse events and the transaminase issue in those slides.

http://www.resverlogix.com/upload/media_element/250/01/rd-day-october-2016---sweeney.pdf